Saturday 10 October 2026
Morning EditionRSS
ZOTPAPER

News without the noise

ZOTPAPER
US Politics

CDC reportedly set to fund controversial newborn hepatitis B vaccine trial in Guinea-Bissau

Outrage grows as $1.6 million earmarked from global health security programs, diverting funds from Ebola response

By LineZotpaper
Published
Read Time2 min
Sources2 outlets
A widely condemned trial that would expose newborns in Guinea-Bissau to hepatitis B is reportedly still being pushed by the Centers for Disease Control and Prevention, with the agency's directors office asking the budget office in late September to set aside $1.6 million to fund it. The trial was suspended in January after international outcry over its unethical design.

The proposal has sparked outrage among health experts, who argue that exposing infants to the virus puts them at high risk of lifelong infection, which can lead to liver cirrhosis, cancer, and premature death. The CDC director's office instructed the agency's budget office to earmark the funds from global health security programs, which might otherwise be used to combat the ongoing Ebola outbreak in the Democratic Republic of the Congo, according to a report from Rolling Stone.

The Department of Health and Human Services, which oversees the CDC, did not respond to a request for comment. The trial's design has been widely condemned by international health bodies, leading to its suspension earlier this year. Reports indicate that HHS Secretary Robert F. Kennedy Jr. remains eager to see the trial proceed, despite the ethical concerns.

The trial would involve administering a hepatitis B vaccine to newborns in Guinea-Bissau in a manner that effectively exposes them to the live virus, rather than protecting them from it. Critics say this violates fundamental ethical principles of medical research, particularly involving vulnerable populations like infants.

§

Analysis

Why This Matters

  • Exposing newborns to a preventable disease that can cause lifelong harm raises profound ethical questions about informed consent and the protection of vulnerable subjects.
  • Diverting $1.6 million from global health security programs could weaken efforts to contain the Ebola outbreak in the DRC, potentially endangering thousands.
  • The outcome could set a precedent for how the US government conducts overseas medical research, particularly under an administration skeptical of established vaccine science.

Background

The trial was suspended in January after an international outcry over its design. It would have involved exposing newborns in Guinea-Bissau to hepatitis B, putting them at high risk of a lifelong infection that can lead to liver disease and premature death. The CDC initially planned to fund the research, but paused amid criticism. Despite the halt, the CDC director's office reportedly told its budget office in late September to set aside $1.6 million for the trial, according to Rolling Stone. The money would come from global health security programs, including funds that could support efforts to fight the current Ebola outbreak in the Democratic Republic of the Congo. HHS Secretary Robert F. Kennedy Jr., a prominent vaccine skeptic, has expressed support for the trial, according to reports.

Key Perspectives

Health experts and critics: The trial is widely condemned as unethical. Exposing newborns to a virus that can cause cancer is unjustifiable, especially when a safe and effective vaccine already exists. The diversion of funds from Ebola response adds to the outrage.

CDC and HHS leadership: Despite the suspension, the CDC director's office has taken steps to secure funding, indicating a determination to proceed. HHS Secretary Kennedy is reportedly eager to push the trial forward, aligning with his long-held skepticism of routine vaccination.

Global health advocates: The potential redirection of resources from Ebola containment to a controversial trial is deeply concerning. The DRC is already struggling to control one of the largest Ebola outbreaks in recent years.

What to Watch

  • Whether HHS formally approves the funding and lifts the suspension on the trial.
  • Reaction from international health organizations such as the World Health Organization, which previously slammed the trial as unethical.
  • Potential Congressional scrutiny or legislation to block the funding.

Sources

Zotpaper

Written by software from the reporting listed above, scored by an automated standards desk, and published without a person reading it first. If something here is wrong, tell the editor and it will be put right.

How we workSubscribe